A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
National Cancer Institute (NCI)
Taiho Oncology, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
Mirati Therapeutics Inc.
DEKA Biosciences
OncoC4, Inc.
Carisma Therapeutics Inc
NGM Biopharmaceuticals, Inc
ENB Therapeutics, Inc
Seoul National University Hospital